Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open-label Study 342 (FREEDOM Study)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yamamoto T. | - |
dc.contributor.author | Lim S.C. | - |
dc.contributor.author | Ninomiya H. | - |
dc.contributor.author | Kubota Y. | - |
dc.contributor.author | Shin W.C. | - |
dc.contributor.author | Kim D.W. | - |
dc.contributor.author | Shin D.J. | - |
dc.contributor.author | Hoshida T. | - |
dc.contributor.author | Iida K. | - |
dc.contributor.author | Ochiai T. | - |
dc.contributor.author | Matsunaga R. | - |
dc.contributor.author | Higashiyama H. | - |
dc.contributor.author | Hiramatsu H. | - |
dc.contributor.author | Kim J.H. | - |
dc.date.available | 2020-06-15T03:35:22Z | - |
dc.date.created | 2020-06-15 | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 2470-9239 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/53473 | - |
dc.description.abstract | Objective: Our study assessed perampanel monotherapy in patients (aged ≥12 years) with focal-onset seizures (FOS) with or without focal to bilateral tonic-clonic seizures (FBTCS) in Japan and South Korea. Methods: Study 342 (NCT03201900; FREEDOM) is a single-arm, open-label, Phase III study. Patients initially received perampanel in a 32-week 4-mg/d Treatment Phase (6-week Titration; 26-week Maintenance Periods). If they experienced a seizure during the 4-mg/d Maintenance Period, they could be up-titrated to 8 mg/d across an additional 30-week Treatment Phase (4-week Titration; 26-week Maintenance Periods). Primary endpoint was the seizure-freedom rate during the Maintenance Period (4 mg/d and last evaluated dose [4 or 8 mg/d]). Secondary endpoints included time to first seizure onset and to withdrawal during Maintenance. Treatment-emergent adverse events (TEAEs) were monitored. Results: At data cutoff (February 28, 2019), 89 patients with FOS (84 [94.4%] with newly diagnosed epilepsy and 5 [5.6%] with recurrence of epilepsy after a period of remission) had received ≥1 perampanel dose; 16 patients discontinued during the 4-mg/d Titration Period, meaning 73 patients entered the 4-mg/d Maintenance Period and were included in the primary analysis set for efficacy. Seizure-freedom rate in the 26-week Maintenance Period was 46/73 (63.0%; 95% confidence interval [CI]: 50.9-74.0) at 4 mg/d and 54/73 (74.0%; 95% CI: 62.4-83.5) at 4 or 8 mg/d. Cumulative probability of seizure-onset and withdrawal rates during Maintenance was 30.8% (95% CI: 21.5-43.0) and 23.7% (95% CI: 15.4-35.3) at 4 mg/d, and 18.2% (95% CI: 11.0-29.3) and 23.3% (95% CI: 15.2-34.8) at 4 or 8 mg/d. Perampanel was generally well tolerated, and the most common TEAE was dizziness. Significance: Perampanel monotherapy (4 to 8 mg/d) was efficacious and consistent with the known safety profile up to 26 weeks in patients (≥12 years) with primarily newly diagnosed FOS with or without FBTCS. © 2020 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Wiley-Blackwell Publishing Ltd | - |
dc.relation.isPartOf | Epilepsia Open | - |
dc.title | Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open-label Study 342 (FREEDOM Study) | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000648552300014 | - |
dc.identifier.doi | 10.1002/epi4.12398 | - |
dc.identifier.bibliographicCitation | Epilepsia Open, v.5, no.2, pp.274 - 284 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85086009291 | - |
dc.citation.endPage | 284 | - |
dc.citation.startPage | 274 | - |
dc.citation.title | Epilepsia Open | - |
dc.citation.volume | 5 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Shin D.J. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | antiepileptic drug | - |
dc.subject.keywordAuthor | focal-onset seizures | - |
dc.subject.keywordAuthor | monotherapy | - |
dc.subject.keywordAuthor | perampanel | - |
dc.subject.keywordAuthor | seizure freedom | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.